Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Omthera Pharmaceuticals, Inc..
Omthera Pharmaceuticals, Inc. is a company.
Key people at Omthera Pharmaceuticals, Inc..
Key people at Omthera Pharmaceuticals, Inc..
Omthera Pharmaceuticals, Inc. was an emerging specialty pharmaceutical company focused on developing therapies for dyslipidemia—abnormalities in blood lipids such as elevated triglycerides—and related cardiovascular diseases.[1][2][4][5][6] Its lead product, Epanova, was an Omega-3 fatty acid formulation that completed Phase III clinical trials to treat patients with high triglyceride levels, aiming to reduce cardiovascular risk; the company served patients with mixed dyslipidemia and partnered with entities like Chrysalis Pharma AG for development and BioVectra Inc. for manufacturing.[1] Founded in 2008 and headquartered in Princeton, New Jersey, Omthera raised $64.01M in funding before being acquired by AstraZeneca in 2013 for further commercialization, including a planned FDA supplemental new drug application.[1][2][3]
Omthera Pharmaceuticals was established in 2008 as a clinical-stage biopharma company targeting unmet needs in lipid management.[1][2] While specific founders are not detailed in available records, the company quickly gained traction through venture backing from firms like New Enterprise Associates (NEA), positioning it for an IPO filing with NASDAQ under ticker OMTH.[4][5][6] A pivotal moment came with the advancement of Epanova through Phase III trials and strategic licensing deals, culminating in its acquisition by AstraZeneca in May 2013, which integrated its pipeline into a major pharma player's cardiovascular portfolio.[1][2][3]
Omthera rode the early 2010s wave of cardiovascular innovation, targeting dyslipidemia amid rising awareness of triglyceride risks beyond cholesterol management, a trend amplified by evolving guidelines from bodies like the National Lipid Association.[3] Timing was ideal post-statin era, with market forces favoring novel Omega-3 therapies amid demands for non-statin options; its 2013 AstraZeneca acquisition ($443M upfront potential) exemplified peer-to-peer M&A in biotech, accelerating Epanova's path while bolstering big pharma's lipid portfolios.[2][3] This influenced the ecosystem by validating specialty dyslipidemia plays, paving the way for subsequent Omega-3 developments like icosapent ethyl (Vascepa) and highlighting VC-to-big-pharma handoffs in cardio-metabolics.[1][2]
Post-acquisition, Omthera effectively ceased independent operations, with Epanova advancing under AstraZeneca—though outcomes like FDA approvals faced hurdles, reflecting biotech risks in late-stage cardio trials. Looking ahead, its legacy endures in AstraZeneca's portfolio amid ongoing triglyceride-focused R&D, shaped by trends like personalized lipid therapies, GLP-1 integrations, and precision cardio. As dyslipidemia markets expand with aging populations and metabolic syndromes, Omthera's model underscores how nimble startups can catalyze big-pharma innovation in high-stakes lipid science.[1][2][3]
